Enhanced Anti-Tumor Effects by Combination of Tucatinib and Radiation in HER2-Overexpressing Human Cancer Cell Lines
L Amrell, E Bär, A Glasow, RD Kortmann, C Seidel… - 2024 - researchsquare.com
Background Tucatinib (TUC), a HER2-directed tyrosine kinase inhibitor, is the first targeted
drug demonstrating intracranial efficacy and significantly prolonged survival in metastatic …
drug demonstrating intracranial efficacy and significantly prolonged survival in metastatic …
Emerging genetic biomarkers in lung adenocarcinoma
Comprehensive genomic profiling is a next-generation sequencing approach used to detect
several known and emerging genomic alterations. Many genomic variants detected by …
several known and emerging genomic alterations. Many genomic variants detected by …
The relationship between statin administration timing and survival outcomes in patients with cancer receiving immune checkpoint blockade
Objective Statins have been demonstrated to improve outcomes in patients receiving
immune checkpoint blockade (ICB). This study aimed to investigate whether the timing of …
immune checkpoint blockade (ICB). This study aimed to investigate whether the timing of …
Co-targeting epigenetic and oncogenic enzymes in HER2+ breast cancer
M Watanabe - 2022 - search.proquest.com
Breast cancer is the most prevalent cancer worldwide with over 2 million women diagnosed
every year, and caused 685,000 deaths globally in 2020. 15–25% of breast cancer patients …
every year, and caused 685,000 deaths globally in 2020. 15–25% of breast cancer patients …
HER2 Aberrations in NSCLC: So Close Yet So Far
G Sartori, L Belluomini, R Trovato, R Minari… - JCO Precision …, 2020 - ascopubs.org
Zhao and Xia 1 wrote a comprehensive review regarding the role of HER2 aberrations in
non–small-cell lung cancer (NSCLC). Although from their analysis, HER2 exon 20 mutations …
non–small-cell lung cancer (NSCLC). Although from their analysis, HER2 exon 20 mutations …
[引用][C] Αλληλούχιση νέας γενιάς και βιοδείκτες για τον μη-μικροκυτταρικό καρκίνο του πνεύμονα
ΧΕ Βασιάδη
Home Evolving Standards of Care HER2 Mutations Present Unique Challenges in NSCLC
HER2 mutations recently joined an expanding list of therapeutically actionable alterations in
non-small cell lung cancer (NSCLC). Of note, trastuzumab deruxtecan was recently granted …
non-small cell lung cancer (NSCLC). Of note, trastuzumab deruxtecan was recently granted …
Reply to G. Sartori et al
J Zhao, Y Xia - JCO precision oncology, 2020 - pubmed.ncbi.nlm.nih.gov
[HTML][HTML] Targeted Therapy Options in NSCLC Expand Further in 2021
K Doherty - 2021 - targetedonc.com
“The number of [known] oncogenic drivers is increasing every year,” Lyudmila A.
Bazhenova, MD, a medical oncologist and professor of medicine at the Moores Cancer …
Bazhenova, MD, a medical oncologist and professor of medicine at the Moores Cancer …
Interrogating Transcriptional and Translational Networks that Promote Metastatic Colonization of the Brain
CM McKernan - 2021 - search.proquest.com
Human epidermal growth factor receptor 2-positive (HER2+) and triple-negative breast
cancer patients often present with brain metastasis. HER2-targeted therapies have not been …
cancer patients often present with brain metastasis. HER2-targeted therapies have not been …